Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Ewing Sarcoma and Hematological Malignancy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FLI1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FLI1 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW confirmed. |
View FLI1 Products |
| Gene Delivery | FLI1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and transcriptional assays. |
View FLI1 Products |
| Benchmark Ab | Anti-FLI1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and ChIP-seq validation. |
View FLI1 Products |
| Validator | FLI1 siRNA Set For target knockdown verification and specificity profiling. |
View FLI1 Products |
| Related Target A | EWSR1 Ewing sarcoma breakpoint region 1; the critical fusion partner forming the oncogenic EWS-FLI1 transcription factor. |
View EWSR1 Products |
| Related Target B | DHX9 RNA Helicase A (RHA); interacts directly with EWS-FLI1 to promote oncogenic transcription. |
View DHX9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intrinsically Disordered Region (IDR) Targetability | High-purity, sequence-verified FLI1 and EWS-FLI1 domain proteins for biophysical binding assays (SPR/MST). |
| Selectivity Over ETS Family Members | Homolog panel screening using sequence-verified ETS family proteins to prevent off-target hematological toxicity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included. |
| False Positives in Transcription Inhibition | Validated siRNA sets included for orthogonal target knockdown and specificity checks. |
Live FLI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FLI1 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted protein degraders (PROTACs/molecular glues) and protein-protein interaction (PPI) disruptors. As first-generation therapies targeting the EWS-FLI1 fusion reach the clinic, the next wave of R&D is targeting the specific epigenetic and transcriptional complexes associated with FLI1 in Ewing Sarcoma and acute myeloid leukemia (AML).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PPI Inhibitors | Oncternal Therapeutics, Salarius Pharmaceuticals | Ewing Sarcoma, Prostate Cancer | Disruption Assay (Need high-purity FLI1 and DHX9/RHA recombinant proteins) |
| PROTACs / Degraders | Arvinas, C4 Therapeutics | Hematological Malignancies, Solid Tumors | Degradation Kinetics (Need validated anti-FLI1 antibodies and siRNA knockdowns) |
| RNA Therapeutics (siRNA/ASO) | Gradalis, Alnylam | Ewing Sarcoma | Transfection & Knockdown Verification (Need sequence-verified FLI1 Lentivirus for rescue assays) |